Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

Intercept Pharmaceuticals advancing on Citi Price Target Hike

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) are higher this morning as a result of Citi raising the price target of the specialty biopharmaceutical company focused on therapeutic  treatment of chronic liver diseases. The previous buy rating was maintained by Citi, but the price target was raised from $600 to $700 a share. Year-to-date, the biopharmaceutical company has outperformed both the Dow Jones and NASDAQ by wide margins.